Skip to content

Assessment of Circulatory Compromise With Ox-Imager Using a Vascular Occlusion Test Protocol

Assessment of Circulatory Compromise With Ox-Imager Using a Vascular Occlusion Test Protocol

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03563105
Enrollment
50
Registered
2018-06-20
Start date
2018-05-30
Completion date
2019-05-01
Last updated
2018-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory; Change

Keywords

tissue oxygen saturation

Brief summary

The objective of this study is to evaluate the performance of Modulated Imaging Inc.'s (MI) next generation Spatial Frequency Domain Imaging (SFDI) system to measure potential circulatory compromise.

Detailed description

The objective of this study is to demonstrate the performance of Modulated Imaging Inc.'s (MI) next generation Spatial Frequency Domain Imaging (SFDI) system, The Ox-Imager Mini. Potential circulatory compromise will be imaged in healthy volunteers using both the subject and predicate devices (Ox-Imager CS) in a Vascular Occlusion Test (VOT) model. The VOT model is an established paradigm to introduce transient ischemia in skin and the the subjects will be imaged during this time. The primary endpoint will be to measure significant decrease in tissue oxygen saturation after occlusion for both predicate and subject devices.

Interventions

DEVICEThe Ox-Imager Mini (Desaturation)

Vascular Occlusion Test

Sponsors

Modulated Imaging Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Vascular Occlusion Test

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Over 18 years of age

Exclusion criteria

* History of congestive heart failure * Patients with existing wound or ulcer. * Rheumatoid arthritis * Pregnant or lactating women

Design outcomes

Primary

MeasureTime frameDescription
Significant decrease in StO2 during occlusionimmediatesignificant decrease in StO2 during occlusion

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026